Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Rodabe N. Amaria"'
Autor:
Sapna Patel, Adi Diab, Michael A. Davies, Jennifer L. McQuade, Michael K. Wong, Isabella C. Glitza, Hussein A. Tawbi, Rodabe N. Amaria, Chantal Saberian, Enrique Alvarez, Amer M. Najjar, Laszlo G. Radvanyi, Cara L. Haymaker, Roland L. Bassett, Silvana C. Faria, Sapna Parshottam, Victor Prieto, Elizabeth J. Shpall
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) are believed to optimally activate antigen-specific T lymphocytes.
Externí odkaz:
https://doaj.org/article/2177a92454d247c7ae2a0821d3eb7f58
Autor:
Michael T. Tetzlaff, Kelly C. Nelson, Adi Diab, Gregg A. Staerkel, Priyadharsini Nagarajan, Carlos A. Torres-Cabala, Beth A. Chasen, Jennifer A. Wargo, Victor G. Prieto, Rodabe N. Amaria, Jonathan L. Curry
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-11 (2018)
Abstract Background Immune checkpoint therapy has dramatically changed the landscape of cancer therapy, providing an efficacious and durable therapeutic option for patients with advanced-stage disease. However, dermatologic toxicities are a well-reco
Externí odkaz:
https://doaj.org/article/702c89c0e6e04f88a481332e31c49761
Autor:
Laszlo Radvanyi, Cara Haymaker, Sapna Pradyuman Patel, Adi Diab, Elizabeth J. Shpall, Roland L. Bassett, Rodabe N. Amaria, Chantal Saberian, Patrick Hwu, Hussein Abdul-Hassan Tawbi, Sapna R. Parshottam, Marie Andrée Forget, Amer Najjar, Jennifer L. McQuade, Michael A. Davies, Gregory Lizée, Chantale Bernatchez, Victor G. Prieto, Cassian Yee, Silvana de Castro Faria, Isabella C. Glitza, Michael K. Wong, Enrique Alvarez
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
BackgroundThe adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) are believed to optimally activate antigen-specific T lymphocytes.
Autor:
Jeniffer McQuade, Rodabe N. Amaria, Hussein Abdul-Hassan Tawbi, Chantal Saberian, Marie Andrée Forget, Gregory Lizée, Michael Davies, Chantale Bernatchez, Patrick Hwu, Roland L. Bassett, Cara Haymaker, Sapna Pradyuman Patel, Adi Diab, Michael K. Wong, Isabella C. Glitza, Cassian Yee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) has shown great benefit in patients with melanoma.1,2 It was suggested that long term tumor immunosurveillance is provided by TIL persisting after transfer.
Autor:
Beth Chasen, Kelly C. Nelson, Priyadharsini Nagarajan, Jennifer A. Wargo, Rodabe N. Amaria, Adi Diab, Gregg A Staerkel, Jonathan L. Curry, Carlos A. Torres-Cabala, Michael T. Tetzlaff, Victor G. Prieto
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-11 (2018)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Immune checkpoint therapy has dramatically changed the landscape of cancer therapy, providing an efficacious and durable therapeutic option for patients with advanced-stage disease. However, dermatologic toxicities are a well-recognized si
Autor:
Scott E. Woodman, Yinghong Wang, Jocelyn Joseph, Noha Abdel-Wahab, Wen-Jen Hwu, Michael K. Wong, Cassian Yee, Hussein Tawbi, Jaime Anderson, Van Anh Trinh, Sapna P. Patel, Patrick Hwu, Chrystia M. Zobniw, Isabella C. Glitza, Daniel H. Johnson, Jennifer E. Davis, Adi Diab, Ali Noman, Junsheng Ma, Rodabe N. Amaria, Michael A. Davies, Marc Uemura, Roland L. Bassett, Hamzah Abu-Sbeih
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-1 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Immune-related enterocolitis (irEC) is the most common serious complication from checkpoint inhibitors (CPIs). The current front-line treatment for irEC, high-dose corticosteroids (CS), have significant side effects and prolonged therapy may reduce C